Open an account

AN2 Therapeutics

ANTX · NASDAQ

$3.56+$0.19 (+5.64%)TodayMarket closed ·
Prev close $3.37

About ANTX

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 21 full-time employees. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Employees
21
Headquarters
Menlo Park, California
Listed
Mar 25, 2022
Sector
Health Care
Industry
Pharmaceuticals
Website
an2therapeutics.com

ANTX key statistics

Market cap
127.17M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
328.11K
Volume
129.74K
Open price
$3.38
High today
$3.59
Low today
$3.36
52 Week high
$7.19
52 Week low
$1.00

AN2 Therapeutics (ANTX) at a glance

AN2 Therapeutics (ANTX) last traded at $3.56, with a market cap of 127.17M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.36 and $3.59. The current price is 6.0% above the day's low and 0.8% below its high.

Volume so far is 129.74K shares, below the average of 328.11K shares a day.

Over the past year AN2 Therapeutics has ranged from $1.00 to $7.19, and now sits 41% of the way up that range.

AN2 Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.2754.

The average analyst price target is $9.18, 157.9% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $9.18
Low
$9.09
Now
$3.56
High
$9.45

ANTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 21.9% on average.

  1. Q3 FY24: reported -$0.35 per share against an estimate of -$0.3927
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.2601
  3. Q1 FY25: reported -$0.35 per share against an estimate of -$0.2649
  4. Q2 FY25: reported -$0.21 per share against an estimate of -$0.3397
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.2244
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.2448
  7. Q1 FY26: reported -$0.29 per share against an estimate of -$0.2346
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.2754

ANTX news

  • Press releaseBusiness Wire

    AN2 Therapeutics to Participate at Upcoming Investor Conferences

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

  • Press releaseBusiness Wire

    AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

  • Press releaseBusiness Wire

    AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

  • Press releaseBusiness Wire

    AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

  • Press releaseBusiness Wire

    AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

Similar companies

Companies in the same industry as AN2 Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.